PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23585819-0 2012 Effect of iron chelators on methemoglobin and thrombin preconditioning. Iron 10-14 coagulation factor II, thrombin Homo sapiens 46-54 26666988-0 2016 Iron and carbon monoxide prevent degradation of plasmatic coagulation by thrombin-like activity in rattlesnake venom. Iron 0-4 coagulation factor II, thrombin Homo sapiens 73-81 26666988-4 2016 Thus, the present investigation sought to determine if pretreatment of plasma with Fe and CO could attenuate venom-mediated catalysis of fibrinogen via thrombin-like activity. Iron 83-85 coagulation factor II, thrombin Homo sapiens 152-160 23578325-6 2013 Thrombin is also added to whole blood exposed to iron, glucose and blood from diabetes and hemochromatosis patients. Iron 49-53 coagulation factor II, thrombin Homo sapiens 0-8 26905070-6 2016 In plasma containing iron and carbon monoxide modified fibrinogen, which may be found in patients at risk of stroke, the coagulation kinetic differences observed with venom was still more vigorous than that seen with thrombin. Iron 21-25 coagulation factor II, thrombin Homo sapiens 217-225 25986992-2 2015 Of interest, SCD patients can become iron overloaded after transfusion, and iron can enhance fibrinogen as a substrate for thrombin, resulting in thrombi that commence coagulation quickly and form rapidly. Iron 76-80 coagulation factor II, thrombin Homo sapiens 123-131 23585819-7 2012 However, if cultures were pretreated with metHb or thrombin plus deferoxamine or 2,2"-bipyridyl, ferritin induction was prevented and cellular redox-active iron increased with hemin treatment. Iron 156-160 coagulation factor II, thrombin Homo sapiens 51-59 22488824-5 2012 Here, we show by means of electron microscopy that iron ions added to human blood dramatically enhances fibrin fibers formation with thrombin, and significantly delays fibrinolysis during spontaneous clotting of native blood. Iron 51-55 coagulation factor II, thrombin Homo sapiens 133-141 21725765-0 2011 Thrombin preconditioning attenuates iron-induced neuronal death. Iron 36-40 coagulation factor II, thrombin Homo sapiens 0-8 22111666-0 2012 Iron levels found in hemochromatosis patients inhibit gamma-thrombin-induced platelet aggregation. Iron 0-4 coagulation factor II, thrombin Homo sapiens 60-68 22111666-4 2012 While performing platelet aggregation studies on hemochromatotic blood samples, it was discovered that the increased serum iron levels associated with this disease almost completely inhibited gamma-thrombin-induced platelet aggregation. Iron 123-127 coagulation factor II, thrombin Homo sapiens 198-206 22111666-5 2012 Further studies were conducted with samples derived from control and hemochromatotic individuals to determine the effects of iron on both alpha- and gamma-thrombin-induced platelet aggregations. Iron 125-129 coagulation factor II, thrombin Homo sapiens 155-163 22111666-6 2012 It was found that gamma-thrombin-induced platelet aggregations were strongly inhibited by the direct binding of iron to these enzymes. Iron 112-116 coagulation factor II, thrombin Homo sapiens 24-32 22111666-8 2012 gamma-Thrombin activity was significantly more sensitive to toxic levels of iron than alpha-thrombin in the activation of the PAR receptors. Iron 76-80 coagulation factor II, thrombin Homo sapiens 6-14 22111666-11 2012 It is unknown, at this time, what specific clinical implications iron inhibition of gamma-thrombin may have, but it is very possible that other conditions caused by hemochromatosis could be exacerbated by the inability of platelets to aggregate normally. Iron 65-69 coagulation factor II, thrombin Homo sapiens 90-98 21725765-10 2011 Preconditioning with thrombin or PAR agonists reduced iron-induced neuronal death (p<0.05). Iron 54-58 coagulation factor II, thrombin Homo sapiens 21-29 20396936-5 2010 Pure iron possessed similar dynamic blood clotting time, prothrombin time and plasma recalcification time to 316L and Mg-Mn-Zn alloy, but a lower hemolysis ratio and a significant lower number density of adhered platelets. Iron 5-9 coagulation factor II, thrombin Homo sapiens 57-68 15759960-7 2005 Although peak serum iron level (340 microg/dL) was significantly lower than that reported to cause hepatotoxicity (>1,700 microg/dL), rapid and significant elevations in aminotransferases (>4,000 U/L), total bilirubin (5 mg/dL), and prothrombin time (50 seconds) occurred within 48 hours. Iron 20-24 coagulation factor II, thrombin Homo sapiens 239-250 20396790-0 2009 Effect of iron ions on functional activity of thrombin. Iron 10-14 coagulation factor II, thrombin Homo sapiens 46-54 20396790-1 2009 The kinetics of thrombin inhibition by irons ions was studied in the thrombin time test with normal plasma. Iron 39-44 coagulation factor II, thrombin Homo sapiens 16-24 20396790-1 2009 The kinetics of thrombin inhibition by irons ions was studied in the thrombin time test with normal plasma. Iron 39-44 coagulation factor II, thrombin Homo sapiens 69-77 20396790-2 2009 The kinetic and concentration characteristics for recovery of thrombin activity by desferal were evaluated at various periods of thrombin incubation with iron ions. Iron 154-158 coagulation factor II, thrombin Homo sapiens 62-70 20396790-4 2009 Pretreatment of iron-containing incubation system with desferal was shown to decelerate the process of thrombin inactivation. Iron 16-20 coagulation factor II, thrombin Homo sapiens 103-111 20396790-6 2009 The effect of reversibility was shown to depend on the time of thrombin preincubation with iron. Iron 91-95 coagulation factor II, thrombin Homo sapiens 63-71 20396790-7 2009 Incomplete recovery of thrombin activity after increasing the time of incubation with iron (more than 30 min) was probably related to oxidative modification of thrombin. Iron 86-90 coagulation factor II, thrombin Homo sapiens 23-31 20396790-7 2009 Incomplete recovery of thrombin activity after increasing the time of incubation with iron (more than 30 min) was probably related to oxidative modification of thrombin. Iron 86-90 coagulation factor II, thrombin Homo sapiens 160-168 14663340-0 2003 Thrombin preconditioning attenuates brain edema induced by erythrocytes and iron. Iron 76-80 coagulation factor II, thrombin Homo sapiens 0-8 15075998-8 2004 Patients with prolonged prothrombin time had significant lower values of haemoglobin, iron, proteins, cholesterol and serum aspartate transaminase, and significantly higher prevalence of diarrhoea, weight loss, abdominal pain and low bone mineral density in comparison with patients with normal prothrombin time. Iron 86-90 coagulation factor II, thrombin Homo sapiens 24-35 33940654-5 2022 Iron scavenging during hemolysis using deferoxamine decreased the ability of the HMVs to enhance thrombin generation. Iron 0-4 coagulation factor II, thrombin Homo sapiens 97-105 14753484-8 2003 Thrombin formation after an ICH may be part of a signaling cascade that acts to limit potentially injurious events associated with clot resolution through altering iron-handling proteins. Iron 164-168 coagulation factor II, thrombin Homo sapiens 0-8 33940654-6 2022 Furthermore, the addition of ferric chloride (FeCl3) to plasma propagated thrombin generation in a FVIII and FIX-dependent manner suggesting that iron positively affects blood coagulation. Iron 146-150 coagulation factor II, thrombin Homo sapiens 74-82 33940654-9 2022 Overall, our results provide evidence for the contribution of iron ions derived from hemolytic RBCs to thrombin generation. Iron 62-66 coagulation factor II, thrombin Homo sapiens 103-111 6421970-4 1984 At iron concentrations comparable to those of previous animal investigations, we reproduced the coagulopathy, in other words, the dose-related prolongation of the prothrombin, thrombin, and partial thromboplastin time, in human plasma in vitro. Iron 3-7 coagulation factor II, thrombin Homo sapiens 166-174 2914136-1 1989 We assessed the ability of platelet sonicates and mediators secreted by unstimulated and thrombin-stimulated platelets to facilitate the release of iron from transferrin. Iron 148-152 coagulation factor II, thrombin Homo sapiens 89-97 2914136-4 1989 Conditioned media from thrombin-stimulated platelets was more effective in mediating the release of iron from transferrin than was conditioned media from unstimulated cells. Iron 100-104 coagulation factor II, thrombin Homo sapiens 23-31 6421970-7 1984 Instead, thrombin was markedly inhibited by iron in its clotting effect on fibrinogen and, specifically, in its fibrinopeptide A-generating capacity, the inhibitory effect being reversible upon iron removal by EDTA chelation and gel filtration. Iron 44-48 coagulation factor II, thrombin Homo sapiens 9-17 6421970-7 1984 Instead, thrombin was markedly inhibited by iron in its clotting effect on fibrinogen and, specifically, in its fibrinopeptide A-generating capacity, the inhibitory effect being reversible upon iron removal by EDTA chelation and gel filtration. Iron 194-198 coagulation factor II, thrombin Homo sapiens 9-17 6421970-8 1984 Thrombin generation in the presence of iron was reduced as well, indicating an inhibition of one or several other enzymes of the intrinsic coagulation cascade. Iron 39-43 coagulation factor II, thrombin Homo sapiens 0-8 6421970-9 1984 Because the amidolytic activity of human thrombin as well as factor Xa, kallikrein, and bovine trypsin was also reversibly suppressed by ferrous sulfate as well as ferric citrate, we consider it likely that the coagulopathy occurring in iron poisoning is the consequence of a general, physiologically important phenomenon: the susceptibility of serine proteases to nontransferrin-bound Fe3+. Iron 237-241 coagulation factor II, thrombin Homo sapiens 41-49 30681741-7 2019 After treatment with intravenous iron, endogenous thrombin potential and peak height decreased in IDA patients by a mean of 122 4 nmol/l/min (95% confidence interval [CI]: 17 9-227, P = 0 023) and 51 9 (95% CI: 26 6-77 2, P < 0 001) respectively. Iron 33-37 coagulation factor II, thrombin Homo sapiens 50-58